Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of a Mineralocorticoid Receptor Antagonist (Spironolactone) in the Treatment of Pulmonary Fibrosis Associated With SARS-CoV-2 Infection

NCT04912011 is registered in ClinicalTrials.gov with Pomeranian Medical University Szczecin as lead sponsor.

NCT NCT04912011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04912011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of a Mineralocorticoid Receptor Antagonist (Spironolactone) in the Treatment of Pulmonary Fibrosis Associated With SARS-CoV-2 Infection
Lead sponsor
Pomeranian Medical University Szczecin
Phase
Phase 4
Overall status
Unknown status
Start date
January 1, 2021
Completion date
December 31, 2021
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pneumonia